Search
Coagulation factor VIIa Recombinant Human
go.drugbank.com/drugs/DB00036ApprovedInvestigationalRecombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. … NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Products: NOVOSEVENRT 5 MG, NOVOSEVEN RT 1 MGCandicidin
go.drugbank.com/drugs/DB01152ApprovedInvestigationalWithdrawnCandicidin is administered intravaginally in the treatment of vulvovaginal candidiasis. … Candicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans).
Antilymphocyte immunoglobulin (horse)
go.drugbank.com/drugs/DB09312ApprovedInvestigationalThere are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes … Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia.
Categories: Immunoglobulin GProducts: ATGAM INJECTION 50 mg/ml, EQUAGAM 50 MG/ML İNFÜZYONLUK ÇÖZELTİ İÇEREN KONSANTRESİ, 5 ADETRespiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigationalthe accompanying vial of AS01E adjuvant as the adjuvant suspension component. … [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]
Synonyms: RSVPreF3 OA, RSVPreF3 OA vaccineAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … The annual average price of Asfotase Alfa treatment is $285,000.
Products: STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETTacrine
go.drugbank.com/drugs/DB00382ApprovedWithdrawnA centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApproximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295]. … Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer.
Products: ERLEADA ®TABLETAS RECUBIERTAS 60 MGEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalCompared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Products: XTANDI 40 MG, XTANDI ® 40 MGNovobiocin
go.drugbank.com/drugs/DB01051ApprovedInvestigationalVet approvedWithdrawnIn 2009, the FDA determined novobiocin sodium was withdrawn from sale for reasons of safety or effectiveness.[L44062,L43942] … (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious
Synonyms: N-{7-[(3-O-carbamoyl-6-deoxy-5-methyl-4-O-methyl-β-D-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamidePoractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalThe phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. … Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B
Products: Curosurf 120 mg - Suspension zur endotracheopulmonalen Instillation, Curosurf 240 mg - Suspension zur endotracheopulmonalen Instillation